Biosimilars | Association for Accessible Medicines
In the News - AAM CEO Dan Leonard shares the industry's 2021 outlook with Chain Drug Review.


Top 10 Ways to Commemorate 10 Years of Biosimilars in the U.S.

U.S. biosimilar medicines are 10 years old this year. It’s been an amazing journey so far, and we see great promise and opportunity ahead, with greater access and lower prices for patients with cancer, Crohn’s disease, rheumatoid arthritis and other conditions. Here are 10 ways to mark this auspicious anniversary:

10. Learn more about the 10th anniversary of the Biologics Price Competition and Innovation Act (BPCIA) at

Jeni's Story — Biosimilars Savings

Jeni Doerr, 35, has recently gone back to school to become a medical coder and when she is not online learning, she is outside enjoying everything California has to offer through hiking, rock climbing and mountain biking with her dog Sally. Jeni takes the biosimilar Inflectra for her pancolitis. She had previously taken a brand biologic, but it didn’t do anything for her symptoms.

"If I'd known I could be on a biosimilar, I'd have done it immediately." —Jeni, Santa Clarita, CA

Celebrate a decade of biosimilar savings at

Christine Simmon: Policy and Biosimilars Sessions at the GRx+Biosims 2020 Virtual Conference

GRx+Biosims is going virtual, join us from around the globe on November 9-11, 2020. You can look forward to the same impactful and news making content you have experienced at past GRx+Biosims events. If you care about generic and biosimilar development, the regulatory process and approvals, and the evolving policy landscape, this is the one conference you cannot afford to miss.

We’ll have:

AAM Commends Introduction of the Increasing Access to Biosimilars Act

WASHINGTON, DC (July 2, 2020) — AAM and its Biosimilars Council commend Senators Cornyn and Bennet for introduction of the Increasing Access to Biosimilars Act. This bipartisan proposal is based on a simple idea – that Medicare policies should encourage the use of the most effective, lowest-cost medicine. Biosimilars consistently deliver savings compared to high-priced brand biologics. We encourage Congress and the Administration to quickly implement this policy and deliver savings to America’s patients and taxpayers.

Subscribe to Biosimilars

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.